Table 5 Circulatory support and postoperative outcome related to incremental quartiles of NT-proBNP on POD3
NT-proBNP POD3< 2167 (n = 81) | NT-proBNP POD3≥2167 to <3610(n = 81) | NT-proBNP POD3≥3610 to <6010 (n = 81) | NT-proBNP POD3≥6010 (n = 82) | p value | |
|---|---|---|---|---|---|
PHF | 4% (3) | 6% (5) | 6% (5) | 21% (17) | 0.001 |
Severe PHF | 1% (1) | 0 | 0 | 6%(5) | 0.01 |
Use of Inotrope | 11% (9) | 22% (18) | 23% (19) | 39% (32) | 0.001 |
Use of IABP | 0 | 0 | 0 | 2% (2) | 0.11 |
Duration of inotropic treatmenta (h) | 3.2 ± 16.9 | 7.2 ± 25.7 | 6.0 ± 14.9 | 18.7 ± 41.9 | 0.004 |
Duration of inotropic treatment b(h) | 29.2 ± 44.8 | 32.6 ± 47.3 | 25.5 ± 21.3 | 47.9 ± 56.1 | 0.61 |
Duration of inotropic treatment > 24 h | 2% (2) | 6% (5) | 9% (7) | 20% (16) | 0.001 |
More than one Inotrope at the same time | 4% (3) | 2% (2) | 4% (3) | 11% (9) | 0.06 |
Adrenalin used | 11% (9) | 19% (15) | 21% (17) | 32% (26) | 0.011 |
Milrinone used | 5% (4) | 7% (6) | 7% (6) | 19% (15) | 0.016 |
Levosimendan used | 1% (1) | 0 | 1% (1) | 6% (5) | 0.035 |
Troponin T POD3 (ng/L) | 180 [100–295] | 210 [120–370] | 250 [130–455] | 490 [230–750] | < 0.0001 |
Delta Troponin T POD3-Pre (ng/L) | 135 [35-220] | 190 [100-355] | 170 [90-340] | 390 [175-600] | < 0.0001 |
ICU stay (h) | 18.2 ± 11.3 | 30.4 ± 55.7 | 22.5 ± 15.6 | 48.7 ± 88.6 | < 0.0001 |
ICU stay > 72 h | 1% (1) | 5% (4) | 2% (2) | 11% (9) | 0.02 |
Ventilation time (h) | 4.0 ± 5.3 | 12.3 ± 52.2 | 5.1 ± 5.0 | 25.9 ± 81.4 | < 0.0001 |
Ventilation time > 48 h | 1% (1) | 2% (2) | 0 | 9% (7) | 0.008 |
AKI | 9% (7) | 10% (8) | 6% (5) | 32% (26) | < 0.0001 |
Postoperative stroke | 0 | 1% (1) | 0 | 4%(3) | 0.11 |
Hospital mortality | 0 | 0 | 0 | 5% (4) | 0.007 |